Erasmus MC Cancer Institute introduces comprehensive DNA testing for CUP cancer patients in EMBRAZE region
The Erasmus MC Cancer Institute has started using comprehensive DNA testing for carcinoma of unknown primary (CUP) cancer patients in the EMBRAZE region. The test identifies which patients are suited for standard cancer treatments, and which patients could benefit from experimental treatments. EMBRAZE is a cancer care network in the provinces of North Brabant and Zeeland.
More information
You read an article in the category Billing code. You may also be interested in Cancer of Unknown Primary, OncoAct or Participating hospitals.All news
Also read
Whole Genome Sequencing feasible in clinical practice
Interim WIDE analysis gives researchers more confidence in a positive outcome. On 21 September 2020, Dr. Kim Monkhorst, who is a …
Antoni van Leeuwenhoek hospital brings comprehensive DNA test closer for all cancer patients
This year, Antoni van Leeuwenhoek hospital joined forces with Hartwig Medical Foundation to deploy the most comprehensive DNA test available …
New cancer treatment options created by full DNA-analysis
Nature publication reports study by Netherlands Center for Personalized Cancer Treatment showing benefits for targeted treatments outside registered indications 2 …
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.